View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Theme
  2. Macro
  3. Covid-19
May 28, 2020

Clover’s adjuvant choice for Covid-19 an edge, but comparison with IMV’s, Novavax’s vaccines limited

By Victoria Smith

Clover Biopharmaceuticals’ Covid-19 adjuvant could benefit over IMV’s and Novavax’s vaccines due to its use of Dynavax Technologies’ FDA-approved adjuvant. However, it is too early to predict a clear leader among the three vaccines due to data gaps such as reproduction platforms to be used in manufacturing, as well as how the spike protein antigen is constructed.

On 25 May, Novavax’s stock jumped to 17% during trading hours after announcing it had enrolled the first participants in its clinical trials, while IMV’s stock rose 20% on 21 May after announcing plans to enter clinical development. Dynavax was up 14% on 24 March upon its collaboration announcement with Clover Biopharmaceuticals. Read more here.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena